1	Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial
2	revascularization.
3	
4	Short Title: Apo(a) size and peripheral revascularization
5	
6	Marianna Pavlyha <sup>1</sup> , Madeleine Hunter <sup>2</sup> , Roman Nowygrod <sup>2</sup> , Virenda Patel <sup>2</sup> , Nicholas
7	Morrissey <sup>2</sup> , Danielle Bajakian <sup>2</sup> , Yihao Li <sup>1</sup> , Gissette Reyes-Soffer <sup>1</sup>
8	
9	Department of Medicine, Division of Preventive Medicine and Nutrition, Columbia University
10	Vagelos College of Physicians and Surgeons, New York, NY
11	<sup>2</sup> Department of Surgery, Division of Vascular Surgery, Columbia University Vagelos College of
12	Physicians and Surgeons, New York, NY
13	
14	Corresponding Author:
15	
16	Gissette Reyes-Soffer
17	630 West 168th street
18	P&S 10th floor, room 501
19	New York, NY 10032
20	Office: (212) 305-9298
21	gr2104@cumc.columbia.edu
22	
23	The authors have no competing interest

2 Type of Research:

1

4

13

20

21

3 Single-center prospective cohort study

**Key Findings:** 

- 6 25 subjects with symptomatic PAD underwent open or
- 7 endovascular lower extremity revascularization in a small
- 8 cohort. Smaller apo(a) isoforms were associated with
- 9 occlusion of the treated lesion(s) within 2-4 weeks
- 10 [OR=1.97 (95% CI 1.01 3.86, p<0.05)], suggesting
- apo(a) isoform size as a predictor of primary patency in
- the early period after lower extremity intervention.

## 14 Take Home Message:

- Subjects with high Lp(a) levels, generally have smaller
- apo(a) isoform sizes. We find that, in this small cohort,
- patients undergoing peripheral arterial revascularization
- subjects with small isoforms are at an increased risk of
- treated vessel occlusion in the perioperative period.

### **Table of Contents Summary**

- 22 Subjects with symptomatic PAD requiring lower
- 23 extremity revascularization have high median Lp(a)

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

to examine the relationship between Lp(a) levels, and wIS with procedural outcomes: symptoms

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

4

(better/worse), primary patency at 2-4 weeks, ABIs, and re-intervention within 3-6 months. We controlled for age, sex, history of diabetes, smoking, statin, antiplatelet and anticoagulation use. Results: Median plasma Lp(a) level was 108 (44, 301) nmol/L. The mean apoB100 level was  $168.0 \pm 65.8$  mg/dL. These values were not statistically different among races. We found no association between Lp(a) levels and wIS with measured plasma pro-inflammatory markers. However, smaller apo(a) wIS was associated with occlusion of the treated lesion(s) in the postoperative period [OR=1.97 (95% CI 1.01 - 3.86, p<0.05)]. The relationship of smaller apo(a) wIS with re-intervention was not as strong [OR=1.57 (95% CI 0.96 - 2.56), p=0.07]. We observed no association between wIS with patient reported symptoms or change in ABIs. Conclusions: In this small study, subjects with smaller apo(a) isoform size undergoing peripheral arterial revascularization were more likely to experience occlusion in the perioperative period and/or require re-intervention. Larger cohort studies identifying the mechanism and validating these preliminary data are needed to improve understanding of long-term peripheral vascular outcomes. Introduction Lipoprotein (a) [Lp(a)] is causal for the development of atherosclerotic cardiovascular disease (ASCVD) and atherothrombosis as shown in epidemiological, Mendelian Randomization, and genome wide association studies (GWAS) <sup>1</sup>. Elevated Lp(a) levels are independently associated with incidence of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after lower extremity endovascular <sup>2</sup> or open surgery <sup>3</sup> while controlling for other risk

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

8

each isoform was reported. Weighted isoform size (wIS) was calculated using the % isoform

markers Interleukin-6 (IL6), Interleukin-18 (IL-18) were measured using ELISA kits (D6050,

R&D Systems, Minneapolis, MN) and (DY318-05, R&D Systems, Minneapolis, MN),

respectively. High sensitivity C-reactive protein (hs-CRP) and Tumor Necrosis Factor alpha

(TNFα) were measured on an Integra 400 plus (Roche) using standardized methods at the Irving

Institute for Clinical and Translational Research Biomarkers laboratory at CUIMC.

### **Statistical Analysis**

have significant CAD<sup>24</sup>.

All data were analyzed using standard R software (Version 4.2.2). Normally distributed variables were summarized by means and standard deviations (SD). Lp(a) levels and TGs were summarized by median and interquartile range. The relationship of Lp(a) levels with *wIS* in the three SRRE groups was studied by Analysis of Variance (ANOVA). Racial differences in Lp(a) levels and *wIS* were assessed using the median test. Due to small samples size, an implementation based on the Firth logistic regression <sup>17</sup>was chosen to examine the relationship between *wIS* with procedural outcomes: change in symptoms, primary patency of treated lesion(s), change in ABIs, and re-intervention within 3-6 months. Results were reported as odds ratios (OR). Sex, age, smoking status, history of diabetes, statin, antiplatelet and DOAC use were considered as potential confounders, according to the literature, and were included in the regression <sup>18 19 20 21</sup>. HTN and BMI were not integrated into the model based on their role in published studies of surgical outcomes <sup>22 23</sup>. We did not control for history of CAD, as literature shows that most individuals with diagnosis of PAD have some degree of CAD and at least 60%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Baseline Characteristics: Subject demographics, lipid and lipoprotein levels are shown in **Table I**. The study population included 12 females and 13 males with a mean age of 66.7±9.7 years. Our cohort was multiethnic with 8 Blacks, 5 Hispanics, and 12 Whites, representative of the available population at our institution. All subjects were Rutherford stage 3 and 4.5 subjects underwent open revascularization and 20, endovascular. Majority of the subjects underwent infra-inguinal intervention (N=23) and 6 required re-intervention within 3-6 months. Individuals were mildly overweight and lipid levels consistent with a population being treated for dyslipidemia. Despite use of lipid lowering therapies, the mean apoB100 levels were 168.0  $\pm$ 65.8 mg/dL. Median plasma Lp(a) level was 108 (44, 301) nmol/L. Primary patency rates at 2-4 weeks and 3-6 months were 76% and 68%. Rate of re-intervention measured at 3-6-months visit was 24%. Lp(a) levels and Isoform Size: Previous reports show that high Lp(a) levels are associated with worse outcomes after surgical intervention. We found that most of the individuals in our cohort had high Lp(a) levels. The mean wIS was  $18.4 \pm 4.1$  and as expected, there was an inverse relationship between Lp(a) levels and wIS ( $R^2 = 0.20$ ; p=0.02), Figure 1. Most individuals express two apo(a) isoforms, however in our small diverse cohort, we found that half (N=12) individuals expressed only a single isoform, Supplemental Table I, with predominance of the small isoform, **Figure 2.** Relationship of Lp(a) levels and Isoforms with surgical outcomes: We did not find significant associations between Lp(a) levels and post-surgical symptoms, ABI, primary patency, or re-

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

intervention, **Table IIb.** Surgery type did not affect this result. However, wIS was significantly correlated with primary patency at 2-4 weeks [OR=1.97 (95% CI 1.01 - 3.86, p<0.05)], **Table IIa.** Controlling for SRRE did not change these study outcomes. We observed a trend between wIS and re-intervention in the 3-6 months period [OR=1.57 (95% CI 0.96 - 2.56), p=0.07)]. When we used predominant apo(a) isoform size as the primary variable in our model, and adjusted for plasma Lp(a) levels, our observed effect of apo(a) size on primary patency remained statistically significant [OR=2.01, (CI 1.03 - 3.93) p<0.05], suggesting that apo(a) was a stronger a predictor of outcomes compared to Lp(a) levels in this cohort. The type of surgical procedure could have affected our study outcomes, however when we assessed the relationship between wIS isoform size and primary patency for subjects that only underwent endovascular intervention, we noted a similar trend [OR=1.67 (95% CI 0.95 - 2.94), p=0.08]. We did not see an association between wIS and patient reported symptoms or change in ABIs at 3-6 months. It is notable, however, that our sample size for analysis of ABIs was much smaller (N=14) due to inability of all subjects to undergo the test reliably (ex. pain, noncompliant calcified vessels resulting in falsely elevated results) or missing measurement from some visits. As expected, inflammatory markers IL-18 and hs-CRP were higher in this cohort when compared to published levels in healthy cohorts, **Table III**. However, we found no significant relationship between plasma Lp(a) levels or wIS with IL-6, IL-18, hs-CRP, or TNFα. Additionally, inflammatory markers were not associated with our surgical outcomes.

### Discussion

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

High Lp(a) levels are associated with adverse limb events in patients with symptomatic PAD undergoing lower extremity revascularization <sup>25</sup> <sup>26</sup> <sup>2</sup>. International guidelines (Canadian <sup>27</sup> and ECC <sup>28</sup>) advocate for all individuals to have Lp(a) measured once in a lifetime. In the United States, the American Heart Association (AHA) suggest using Lp(a) levels as a 'risk enhancer'<sup>29</sup>. However, there are no specific guidelines for Lp(a) measurements in patients with advanced PAD that are referred for surgical intervention. All subjects in our study have been diagnosed with at least one metabolic disease, however, they were not screened for Lp(a) by their primary providers; and the majority were found to have elevated levels. Although our study sample is small, which limits the generalizability of the results, it features a good representation based on gender and race. These data can be used to develop well controlled cross-sectional studies that can examine the role of apo(a) in larger populations with PAD. Most individuals at risk or that have ASCVD, obtain laboratory measurement of low-density lipoprotein cholesterol (LDL-C), an apoB100 containing particle. Physicians rely on these measurements for prescribing lipid therapies, such as statins, in clinical practice. We observed that in our cohort, 76% of individuals were prescribed statins. While statins significantly lower LDL-C, they tend to increase Lp(a) by about 11% <sup>1</sup>. It is important to note, however, that the laboratory levels of LDL-C in plasma are known to be confounded by the presence of Lp(a)-C<sup>30</sup>, which contains both apoB100 and apo(a). The reason for this overlap lies in similar plasma densities between Lp(a) and LDL particles. Thus, in patients with high levels of Lp(a) the actual LDL-C is lower from the reported value and some investigators believe apoB100 to be a more accurate measure of cardiovascular risk compared to LDL-C<sup>31</sup>. This is important, because most

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

vascular patients are prescribed statins, which works via increased LDL receptor expression, facilitating clearance of LDL-C, but not Lp(a). Patients that have elevated LDL-C while on optimal LDL lowering therapy would benefit from having their Lp(a) measured and treated, as there is a high probability that the increased cholesterol is carried by Lp(a) particles. We observe this in some patients in our population as well and this may explain why some patients, despite LDL-C lowering by statins, remain at risk<sup>32</sup>. Two out of 19 subjects in the study who were taking statins had above normal LDL-C levels; both had Lp(a) measurements > 200 nmol/L. In this population where Lp(a) is high, this particle may carry most of the cholesterol. Whereas there has been great interest in Lp(a) levels and surgical outcomes, few studies have looked at the role of apo(a) size in vascular surgery, and specifically, there are no existing reports on patency after lower extremity revascularization. The LPA gene encodes for two apo(a) isoforms that comprise the Lp(a) particle. Variations in size of the apo(a) isoforms are driven by the number of KIV-2 repeats. Small number of KIV-2 repeats lead to small apo(a) size and are associated with higher Lp(a) levels, posing an increased risk for cardiovascular disease, including PAD <sup>9</sup>. Similar to other cohorts <sup>1</sup>, the current study finds an inverse association between plasma Lp(a) levels and apo(a) allele size, with smaller isoforms associated with higher Lp(a) levels<sup>33</sup>. Whereas ~20% of the general population is expected to have high Lp(a) and express two apo(a) isoforms<sup>1</sup>, close to half of our subjects with high median Lp(a) expressed only one isoform size, **Supplemental Table I**. Previous studies in individuals with PAD showed that both increased Lp(a) serum concentrations (75th percentile) and the small apo(a) phenotype are strongly associated with symptomatic PAD, independent of other confounders <sup>9</sup>. We did not see any significant correlation between Lp(a) levels and outcomes, but when controlled for Lp(a)

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

levels, the predictive association of wIS with primary patency was still statistically significant. Although data in the literature regarding disease predictability of Lp(a) vs apo(a) is conflicting, there is evidence that the strength of the association is higher for apo(a) isoform size in certain diseases<sup>34</sup>. To our knowledge, there are no reports assessing the correlation between apo(a) size and primary patency. Our preliminary study finds that small apo(a) size strongly correlates with primary patency within 2-4 weeks with a trend towards a higher rate or re-intervention at 3-6 months. Although more comprehensive evaluation of the prognostic relationship between apo(a) size and these outcomes of peripheral arterial interventions would be served in a randomized or cross-sectional study, these results support what is already known about apo(a)'s mode of action. We postulate that the probable mechanisms lie in the apo(a)'s kringle structure having homology with fibrinolytic proenzyme plasminogen, but inactive in fibrinolysis. Small apo(a) isoform size resulting from low LPA KIV-2 number of repeats can slow fibrinolysis and thus indirectly promote thrombosis, leading to increased risk of perioperative complications such as graft occlusion or thromboembolic events <sup>35</sup>. Additionally, apo(a) potentiates thrombosis by binding and inactivating tissue factor pathway inhibitor (TFPI)<sup>36</sup>. This is especially important, as many of peripheral arterial intervention are performed to aid in wound healing and this period may be imperative for patients with tissue loss. These pro-thrombotic action of the apo(a) could also explain the high rate of early re-intervention in this cohort of patients with high Lp(a), particularly as 5 our 6 subjects in the group requiring re-intervention had small apo(a), Supplemental Figure 1. A study from a UK biobank studied approximately 460 thousand participants and showed significant differences in Lp(a) concentrations across racial subgroups, specifically with higher

5

7

8

9

12

13

15

17

18

19

22

23

Lp(a) levels seen within South Asian and Black population compared to Whites <sup>37</sup>. Although on 1 2 average Hispanics had higher values than Whites in our cohort, there we no statistically significant differences in Lp(a) values and apo(a) size among different races and race had no 4 impact on most surgical outcomes. This could be due to our limited sample size. 6 Some of Lp(a)'s role in disease risk has been linked to inflammatory profiles. Specifically, elevated TNF-α, IL-6, and CRP levels 12,38 at baseline correlate with worse vascular outcomes in patients with diabetes, PAD, and chronic limb-threatening ischemia undergoing endovascular procedures <sup>14</sup>. We did not find any significant correlations with circulating inflammatory markers 10 and Lp(a), wIS or surgical outcomes, however, we did not measure OxPLs which may add new information in PAD patients as it has in other described populations <sup>39</sup>. Of note, it has also been 11 reported that statins decreased the serum levels of hs-CRP<sup>12</sup> and downregulate IL-6<sup>13</sup>. Majority of our subject were taking high-dose statins (which also tend to increase Lp(a)) and may be 14 contributing to our observations. Although there are no currently available targeted therapies to treat high Lp(a), some agents 16 available in the United States that lower apoB100 and LDL-C also decrease Lp(a) modestly, such as niacin, Ezetimibe, and PSCK9 inhibitors. The FDA has also recently approved lipoprotein apheresis for high-risk cases with Lp(a) >60mg/dL and LDL-C >100 mg/dL and with either documented CAD or PAD<sup>1</sup>. The two apo(a) targeted therapies, antisense oligonucleotides 20 21 and siRNA and are also in phase 3 studies are expected to report their initial results in 2024. While we wait for this data, new studies now suggest the benefit of DAPT in patients with high Lp(a)<sup>40</sup>. Particularly, recent outcomes in these patients undergoing percutaneous coronary

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

intervention (PCI), showed that prolonged DAPT (>1 year) reduced ischemic cardiovascular events, all-cause mortality, cardiac mortality, and definite/probable stent thrombosis, without increase in clinically relevant bleeding risk compared with < 1-year DAPT <sup>41</sup>. Data from this small study cohort raise the question whether we need to rethink risk assessment and postoperative management in patients high Lp(a) and small apo(a) size undergoing lower extremity interventions. As the importance of Lp(a) becomes more recognized in clinical practice<sup>37,42</sup>, and we review cardiovascular outcome data from phase 3 apo(a) targeted treatments, developing larger studies that have more stringent control of patient selection and type of intervention would serve as the next step in validating the generalizability of the current findings. Understanding the impact of apo(a) isoform size on Lp(a) levels and surgical outcomes may guide risk stratification and therapeutic decision-making when it comes to pre-operative optimization and medical management post-operatively. Lp(a) levels are stable throughout lifetime. Although measuring apo(a) size may not be feasible in all patients and it currently not used in clinical practice, as genetic testing becomes more widely available, assessing KIV-2 size associated with the LPA gene may help identify individuals at higher risk of developing PAD and worse outcomes. Given Lp(a) genetic predisposition and low variability of levels throughout lifetime, one measurement may be sufficient and is the standard of care in many European countries<sup>28</sup>. Further research in larger cohorts is needed to establish a more robust understanding of the mechanisms and impact of apo(a) isoform size on surgical outcomes in patients PAD.

could be an important risk predictor not only for the development of PAD, which has already

studies identifying the mechanism and relationship of these findings to long-term peripheral

been established in literature, but also as a driver of worse short term surgical outcomes. Further

20

21

- 1 vascular outcomes are warranted, specifically identifying the role of apo(a) size among different
- 2 sexes and races in larger well controlled cohorts.

### Acknowledgements

3

4

- 5 We would like to acknowledge Anastasiya Matveyenko<sup>1</sup> and Srinivas Cherukuri<sup>1</sup> for their
- 6 assistance with study conduction and laboratory measurements. **Funding** for this study was
- 7 provided by T32HL007343 (M.P.), UL1TR001873 (G.R.S), partial funding for MP stipend and
- 8 manuscript processing funds were supported by a donation from Robin Chemers Neustein to the
- 9 Reyes-Soffer Laboratory.

#### References

1

- Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48-e60.
- Tomoi Y, Takahara M, Soga Y, Kodama K, Imada K, Hiramori S, Ando K. Impact of High
   Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy.
   JACC Cardiovasc Interv. 2022;15:1466-1476. doi: 10.1016/j.jcin.2022.05.050
- Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J, Hazenberg
   C, de Kleijn DPV. High lipoprotein(a) is associated with major adverse limb events after
   femoral artery endarterectomy. *Atherosclerosis*. 2022;349:196-203. doi:
   10.1016/j.atherosclerosis.2021.11.019
- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and
   Emerging Therapies. J Am Coll Cardiol. 2017;69:692-711. doi: 10.1016/j.jacc.2016.11.042
- Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. *J Am Coll Cardiol*. 2006;47:2219-2228. doi: 10.1016/j.jacc.2006.03.001
- 22 6. Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements: 23 Lipoprotein(a) and inflammation. *Pharmacol Res.* 2021;169:105689. doi: 24 10.1016/i.phrs.2021.105689
- Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of
   lipoprotein (a). *J Lipid Res.* 2016;57:1339-1359. doi: 10.1194/jlr.R067314
- 27 8. Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated 28 lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic 29 review. *Vasc Med.* 2022;27:385-391. doi: 10.1177/1358863X221091320
- Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M,
   Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low
   molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic
   peripheral arterial disease. *Clin Chem*. 2007;53:1298-1305. doi:
   10.1373/clinchem.2007.088013
- Molgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant
   association between low-molecular-weight apolipoprotein(a) isoforms and intermittent
   claudication. Arterioscler Thromb. 1992;12:895-901. doi: 10.1161/01.atv.12.8.895
- Ezhov MV, Safarova MS, Afanasieva Ol, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a)
   level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular
   outcomes after coronary artery bypass grafting. *Atherosclerosis*. 2014;235:477-482. doi: 10.1016/j.atherosclerosis.2014.05.944
- 42 12. Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S,
   43 Mohammadi K, Jamialahmadi T, Reiner Z, et al. Effect of Statins on Serum level of hs 44 CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-

- Analysis of Randomized Controlled Trials. *Mediators Inflamm*. 2022;2022:8732360. doi: 10.1155/2022/8732360
- Sepehri Z, Masoumi M, Ebrahimi N, Kiani Z, Nasiri AA, Kohan F, Sheikh Fathollahi M, Kazemi Arababadi M, Asadikaram G. Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. *PLoS One*. 2016;11:e0168312. doi: 10.1371/journal.pone.0168312
- 7 14. Biscetti F, Ferraro PM, Hiatt WR, Angelini F, Nardella E, Cecchini AL, Santoliquido A,
  8 Pitocco D, Landolfi R, Flex A. Inflammatory Cytokines Associated With Failure of Lower9 Extremity Endovascular Revascularization (LER): A Prospective Study of a Population
  10 With Diabetes. *Diabetes Care*. 2019;42:1939-1945. doi: 10.2337/dc19-0408
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ,
   Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, et al.
   Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med.
   2020;382:244-255. doi: 10.1056/NEJMoa1905239
- 16. Mohammedi K, Pigeyre M, Bosch J, Yusuf S, Gerstein HC. Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study. *Eur Heart J*. 2024. doi: 10.1093/eurheartj/ehae087
- 17. loannis Kosmidis ECKP, Nicola Sartori Mean and median bias reduction in generalized
   linear models. Statistics and Computing. 2020;30:43-59. doi:
   https://doi.org/10.1007/s11222-019-09860-6
- 21 18. European Society of Hypertension-European Society of Cardiology Guidelines C. 2003 22 European Society of Hypertension-European Society of Cardiology guidelines for the 23 management of arterial hypertension. *J Hypertens*. 2003;21:1011-1053. doi: 24 10.1097/00004872-200306000-00001
- Yap T, Silickas J, Weerakkody R, Lea T, Santhirakumaran G, Bremner L, Diamantopoulos
   A, Biasi L, Thomas S, Zayed H, et al. Predictors of outcome in diabetic patients
   undergoing infrapopliteal endovascular revascularization for chronic limb-threatening
   ischemia. J Vasc Surg. 2022;75:618-624. doi: 10.1016/j.jvs.2021.09.040
- 29 20. Giovanetti F, Gargiulo M, Laghi L, D'Addato S, Maioli F, Muccini N, Borghi C, Stella A.
  30 Lipoprotein(a) and other serum lipid subfractions influencing primary patency after
  31 infrainguinal percutaneous transluminal angioplasty. *J Endovasc Ther*. 2009;16:389-396.
  32 doi: 10.1583/09-2733.1
- Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M, Ishihara M. Impact of lipoprotein(a) levels on primary patency after endovascular therapy for femoropopliteal lesions. *Heart Vessels*. 2023;38:171-176. doi: 10.1007/s00380-022-02151-7
- Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS,
   Blomster JI, Fowkes FGR, Katona BG, et al. Association of Hypertension and Arterial
   Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery
   Disease: The EUCLID Trial. *Circ Cardiovasc Qual Outcomes*. 2020;13:e006512. doi:
   10.1161/CIRCOUTCOMES.120.006512
- 42 23. Arinze N, Farber A, Levin SR, Cheng TW, Jones DW, Patel VI, Rybin D, Doros G, Siracuse 43 JJ. Perioperative outcomes after lower extremity bypass and peripheral vascular

- interventions in patients with morbid obesity and superobesity. *J Vasc Surg.* 2020;71:567-574 e564. doi: 10.1016/j.jvs.2019.05.039
- Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J, McBride PE.
   Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. *Vasc Med*. 2003;8:233-236. doi: 10.1191/1358863x03vm506ra
- Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, Doi J, Utsugi Y, Sudo Y, Kimura S, et al. Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions. *J Endovasc Ther*. 2017;24:793-799. doi: 10.1177/1526602817728068
- 26. Guedon AF, De Freminville JB, Mirault T, Mohamedi N, Rance B, Fournier N, Paul JL,
   Messas E, Goudot G. Association of Lipoprotein(a) Levels With Incidence of Major
   Adverse Limb Events. JAMA Netw Open. 2022;5:e2245720. doi:
   10.1001/jamanetworkopen.2022.45720
- Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA,
   Genest J, Gregoire J, Grover SA, et al. 2021 Canadian Cardiovascular Society Guidelines
   for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in
   Adults. Can J Cardiol. 2021;37:1129-1150. doi: 10.1016/j.cjca.2021.03.016
- Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR,
   Koschinsky M, Lambert G, Mach F, et al. Lipoprotein(a) in atherosclerotic cardiovascular
   disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
   Eur Heart J. 2022;43:3925-3946. doi: 10.1093/eurheartj/ehac361
- 29. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de
   Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018
   AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
   the Management of Blood Cholesterol: Executive Summary: A Report of the American
   College of Cardiology/American Heart Association Task Force on Clinical Practice
   Guidelines. J Am Coll Cardiol. 2019;73:3168-3209. doi: 10.1016/j.jacc.2018.11.002
- Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. *J Clin Lipidol*. 2018;12:702-710. doi: 10.1016/j.jacl.2018.02.014
- 31. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference
   BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA* Cardiol. 2019;4:1287-1295. doi: 10.1001/jamacardio.2019.3780
- 35 32. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM,
   36 Misra S, Ujueta F, American Heart Association Council on E, et al. Lower Extremity
   37 Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future
   38 Directions: A Scientific Statement From the American Heart Association. *Circulation*.
   39 2021;144:e171-e191. doi: 10.1161/CIR.000000000001005
- 40 33. Matveyenko A, Matienzo N, Ginsberg H, Nandakumar R, Seid H, Ramakrishnan R,
  41 Holleran S, Thomas T, Reyes-Soffer G. Relationship of apolipoprotein(a) isoform size
  42 with clearance and production of lipoprotein(a) in a diverse cohort. *J Lipid Res*.
  43 2023;64:100336. doi: 10.1016/j.jlr.2023.100336

- Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V,
   Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. *Arterioscler Thromb Vasc Biol.* 1996;16:713-719. doi:
- 4 10.1161/01.atv.16.6.713

- 5 35. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res.* 2016;57:745-757. doi: 10.1194/jlr.R060582
- 7 36. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Jr., Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. *Blood*. 2001;98:2980-2987. doi: 10.1182/blood.v98.10.2980
- 37. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a)
   (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease:
   New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol.
   2021;41:465-474. doi: 10.1161/ATVBAHA.120.315291
- Sepehri Z, Masoumi M, Ebrahimi N, Kiani Z, Nasiri AA, Kohan F, Fathollahi MS, Arababadi MK, Asadikaram G. Correction: Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. *PLoS One*. 2017;12:e0172404. doi: 10.1371/journal.pone.0172404
- 39. Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. *J Am Coll Cardiol*. 2013;61:2169-2179. doi: 10.1016/j.jacc.2013.02.047
- Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, Bhatt DL, Storey
   RF, Sabatine MS, O'Donoghue ML. Lipoprotein(a) and Benefit of Antiplatelet Therapy:
   Insights From the PEGASUS-TIMI 54 Trial. *JACC: Advances*. 2023;2. doi:
   10.1016/j.jacadv.2023.100675
- Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, Zhang R, Wang H, Cai Z, Feng L, et al. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable
   Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After
   Percutaneous Coronary Intervention? J Am Heart Assoc. 2022;11:e023578. doi: 10.1161/JAHA.121.023578
- Marlys L. Koschinsky AB, Michael B. Boffa, Dave L. Dixon, Keith C. Ferdinand, Samuel S.
   Gidding, et al. A Focused Update to the 2019 NLA Scientific Statement on Use of
   Lipoprotein(a) in Clinical Practice. *Journal of Clinical Lipidology*. 2024.

Characteristic	Study Sample			
Age, y	$66.7 \pm 9.7$			
Range for age	43-79			
BMI, kg/m <sup>2</sup>	28.1 ± 5.3			
Race	Female (N=12	(2) Mo	ale (N=13)	
White	5		7	
Black	3		5	
Hispanic	4		1	
Clinical Characteristics, n(%)				
Diabetes mellitus		14 (56%)		
Hypertension		21 (84%)		
Hyperlipidemia		20 (80%)		
History CAD		7 (28%)		
Prior coronary event		4 (16%)		
Ever smoker		20 (80%)		
Medical therapy, n(%)				
Statin		19 (76%)		
Beta-blocker		12 (48%)		
DAPT or $AP + DOAC$		22 (88%)		
DOAC alone	1 (4%)			
AP alone	2 (8%)			
Total cholesterol, mg/dL	$159 \pm 46.1$			
Triglycerides, mg/dL	148 (105, 238)			
HDL-C, mg/dL	$39.8 \pm 14.0$			
Calculated-LDL, mg/dL*	$78.7 \pm 34.8$			
Apo(a) weighted isoform size	18.4 + 4.1		$18.4 \pm 4.1$	
Tpo(u) worghton isotoriii size	Black	Hispanic	White	
Plasma Lp(a), nmol/L	68.3 (34.0, 304.1)	228.6 (67.0, 333.0)	125.9 (80.1, 191.3)	
Plasma apoB100, mg/dL	167.7 ± 45.1	225.6 ± 83.7	144.3 ± 59.2	

Legend: ± represents Mean and Standard Deviation; ( ) represents Median and Interquartile Range.

\*Calculated LDL-C means reported for N=24, one subject had >400 mg/dL TG levels (Supplemental Table I).

Coronary artery disease (CAD); direct oral anticoagulant (DOAC), antiplatelet (AP), dual antiplatelet therapy (DAPT)

**Table IIa.** Effects of apo(a) wIS on surgical outcomes

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
Δ Symptoms	25	0.25 (-1.01, 1.50)	p=0.70
Primary patency	23	-2.81 (-5.57, -0.04)	p <0.05*
Δ ΑΒΙ	14	0.30 (-2.43, 3.01)	p=0.84
Re-Intervention	25	-0.53 (-2.59, 1.54)	p=0.07

**Table IIb.** Effects of Lp(a) on surgical outcomes

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
Δ Symptoms	25	0.17 (-0.89, 1.23)	p=0.75
Primary patency	23	0.32 (-0.68, 1.33)	p=0.53
Δ ΑΒΙ	14	0.92 (-1.57, 3.41)	p=0.47
Re-intervention	25	0.13 (-0.89, 1.15)	p=0.80

Legend: PAD: Peripheral Arterial Disease; wIS: weighted Isoform Size;  $\Delta$  ABI: change in Ankle Brachial Index;  $\Delta$  Symptoms: change in symptoms, wIS and Lp(a) were standardized, \*statistical significance = p < 0.05; Firth model: exponential estimate (95% CI). Available number of subject data for each outcome (N=X) are provided. Complete ABI data is missing in 11 subjects


Table III. Comparison of inflammatory marker levels in Study Subjects and Healthy Controls.

Marker	PAD Cohort	*Healthy Controls
IL-6 (pg/mL)	3.3±2.5	0.01-11.5 38
IL-18 (pg/mL)	274.2±147.5	80–120 39
hs-CRP (mg/dL)	3.6±4.6	<0.3 40
TNFα (pg/mL)	1.4±0.7	0 - 2.2

Legend: ± represents Mean and Standard Deviation; IL: Interleukin; CRP: C-reactive protein; TNF: Tumor Necrosis


Factor. Study Cohort N=25. \*Healthy controls from published literature

# **Figure 1.** Negative relationship between Lp(a) levels and wIS



4 Legend: Lp(a): Lipoprotein(a); wIS: weighted Isoform Size.

# **Figure 2.** Apo(a) size distribution by Lp(a) level quartiles (nmol/L)



- 3 Legend: Lp(a): Lipoprotein(a). Gray: small apo(a) isoforms; Black: large apo(a) isoforms. All data presented as
- 4 percentages of study subjects and absolute numbers in ().

1

2

## **Supplemental Data**

1

3


4

### Supplemental Table I. Individual Subject Data

Subject	Lp(a)	T 0 4	%	T 0 0	%	TO	CDDE
Number	(nmol/L)	Isoform 1	Isoform 1	Isoform 2	Isoform 2	wIS	SRRE
1	300.99	14	8%	25	18%	15.98	В
2	97.10	17	97%	21	3%	17.12	W
3	92.56	20	78%	31	22%	22.42	W
4	3.40	19	82%	30	18%	20.98	В
5	4.12	27	100%			27	В
6	73.82	14	78%	26	22%	16.64	В
7	193.26	18	100%			18	W
8	190.63	13	100%			13	W
9	228.60	18	82%	24	18%	19.08	Н
10	43.91	28	96%	34	4%	28.24	В
11	397.62	17	100%			17	Н
12*	305.28	16	100%			16	W
13	108.34	13	91%	18	9%	13.45	W
14	448.08	17	100%			17	W
15	332.96	14	90%	13	10%	13.9	Н
16	42.62	13	99%	29	1%	13.16	W
17	313.38	17	100%			17	В
18	<2.80	15	100%			15	W
19	63.84	24	100%			24	В
20	42.47	19	84%	24	16%	19	Н
21	156.73	19	100%			19	W
22	67.04	23	100%			23	Н
23	7.05	15	81%	32	19%	18.23	W
24	143.43	21	100%			21	W
25	556.02	14	99%	29	1%	14.15	В


Legend: wIS – weighted Isoform Size; SRRE – Self Reported Race/Ethnicity. B-Black, W-White, H-Hispanic. Large isoform ≥22, Small isoform<22. \*Calculated LDL-C not reported (TG levels >400 mg/dL).

## **Supplemental Figure 1.** Apo(a) weighted isoform sizes in re-operative patients



Legend: wIS – weighted Isoform Size, Subject Number (N) underwent re-operation at 3-6 months.

L3



Legend: LE—lower extremity; US—ultrasound; ABI—ankle brachial index; N—sample number